China Pharma Holdings Inc (CPHI) - Cash Flow Conversion Efficiency
Based on the latest financial reports, China Pharma Holdings Inc (CPHI) has a cash flow conversion efficiency ratio of -0.028x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-236.99K) by net assets ($8.49 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See how leveraged is China Pharma Holdings Inc's balance sheet to measure how much of total assets are equity-financed.
China Pharma Holdings Inc - Cash Flow Conversion Efficiency Trend (2001–2024)
This chart illustrates how China Pharma Holdings Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check China Pharma Holdings Inc earnings quality ratio to evaluate the quality of earnings relative to operating cash generation.
China Pharma Holdings Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of China Pharma Holdings Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
NAYA Biosciences, Inc
NASDAQ:NAYA
|
-0.048x |
|
Fenbo Holdings Limited Ordinary Shares
NASDAQ:FEBO
|
-0.054x |
|
Chanson International Holding Class A Ordinary Shares
NASDAQ:CHSN
|
0.073x |
|
Thrive Tribe Technologies Ltd
AU:1TT
|
-1.889x |
|
PolyPlank publ AB
ST:POLY
|
0.323x |
|
Scout Security Ltd
AU:SCT
|
-0.203x |
|
John Wood Group PLC
LSE:WG
|
-0.763x |
|
Netcall plc
LSE:NET
|
0.012x |
Annual Cash Flow Conversion Efficiency for China Pharma Holdings Inc (2001–2024)
The table below shows the annual cash flow conversion efficiency of China Pharma Holdings Inc from 2001 to 2024. For the full company profile with market capitalisation and key ratios, see China Pharma Holdings Inc (CPHI) total market value.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $7.75 Million | $-466.36K | -0.060x | +35.87% |
| 2023-12-31 | $7.45 Million | $-699.69K | -0.094x | +1.68% |
| 2022-12-31 | $4.29 Million | $-409.55K | -0.095x | -129.95% |
| 2021-12-31 | $6.02 Million | $-249.84K | -0.042x | -686.36% |
| 2020-12-31 | $8.00 Million | $-42.26K | -0.005x | -108.02% |
| 2019-12-31 | $9.24 Million | $608.31K | 0.066x | +58.21% |
| 2018-12-31 | $30.20 Million | $1.26 Million | 0.042x | +113.12% |
| 2017-12-31 | $43.07 Million | $841.22K | 0.020x | -60.27% |
| 2016-12-31 | $58.91 Million | $2.90 Million | 0.049x | +6.59% |
| 2015-12-31 | $72.64 Million | $3.35 Million | 0.046x | +7.17% |
| 2014-12-31 | $106.25 Million | $4.57 Million | 0.043x | -33.45% |
| 2013-12-31 | $132.94 Million | $8.60 Million | 0.065x | +163.53% |
| 2012-12-31 | $148.52 Million | $3.64 Million | 0.025x | -33.25% |
| 2011-12-31 | $142.48 Million | $5.24 Million | 0.037x | -44.32% |
| 2010-12-31 | $117.94 Million | $7.79 Million | 0.066x | -44.07% |
| 2009-12-31 | $90.40 Million | $10.67 Million | 0.118x | +26.02% |
| 2008-12-31 | $69.87 Million | $6.54 Million | 0.094x | +32.90% |
| 2007-12-31 | $39.76 Million | $2.80 Million | 0.070x | +184.62% |
| 2006-12-31 | $20.85 Million | $-1.74 Million | -0.083x | -115.89% |
| 2005-12-31 | $-68.32K | $-35.81K | 0.524x | 0.00% |
| 2004-12-31 | $-68.32K | $-35.81K | 0.524x | +313.11% |
| 2003-12-31 | $-733.96K | $-93.13K | 0.127x | -75.98% |
| 2002-12-31 | $-566.35K | $-299.20K | 0.528x | 0.00% |
| 2001-12-31 | $-566.35K | $-299.20K | 0.528x | -- |
About China Pharma Holdings Inc
China Pharma Holdings, Inc. develops, manufactures, and markets pharmaceutical products for human use in the People's Republic of China. The company provides products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. Its products include Cerebroprotein Hydroloysate injection to treat memory decline and attention deficit; Gastrodin inje… Read more